Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part
in this study. This research is being done because current treatment does not help everyone
with this disease. The purpose of this study is to find out what effects (good and bad) the
drug thalidomide has on patients and the lymphoma. Thalidomide has been shown to have
activity against other cancers but is not approved by the FDA for treatment of lymphoma.
Thalidomide prevents growth of new blood vessels that allow cancer cells to receive
nourishment and spread. Another reason for doing the study is that researchers want to learn
more about how the drug works and whether some patients respond better than others.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
L. Thompson Heffner, MD
Emory University Winship Cancer Institute
United States: Institutional Review Board
|Emory University Winship Cancer Institute||Atlanta, Georgia 30322|